Clinical Trial Update: Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating conivaptan for correcting hyponatremia in neurological patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Conivaptan (conivaptan)

Snippet

Sponsor: Columbia University | Conditions: Hyponatremia | Phase 3 | Status: WITHDRAWN